Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

The risk of fetal anomalies as a result of progesterone therapy during pregnancy.

Check JH, Rankin A, Teichman M.

Fertil Steril. 1986 Apr;45(4):575-7.

PMID:
3956772
2.

Fetal malformations following progesterone therapy during pregnancy: a preliminary report.

Rock JA, Wentz AC, Cole KA, Kimball AW Jr, Zacur HA, Early SA, Jones GS.

Fertil Steril. 1985 Jul;44(1):17-9.

PMID:
4007191
3.

Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974.

Resseguie LJ, Hick JF, Bruen JA, Noller KL, O'Fallon WM, Kurland LT.

Fertil Steril. 1985 Apr;43(4):514-9.

PMID:
3987922
4.

Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy.

Dudás I, Gidai J, Czeizel AE.

Congenit Anom (Kyoto). 2006 Dec;46(4):194-8.

PMID:
17096820
5.

Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial.

Reijnders FJ, Thomas CM, Doesburg WH, Rolland R, Eskes TK.

Br J Obstet Gynaecol. 1988 May;95(5):462-8.

PMID:
3135831
6.
8.

Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine.

Jones KL, Johnson KA, Dick LM, Felix RJ, Kao KK, Chambers CD.

Teratology. 2002 Mar;65(3):125-30.

PMID:
11877776
9.

Origin of first trimester 17-hydroxyprogesterone levels as determined in pregnancies by donor oocyte fertilization.

Check JH, Barnea ER, Shapse DB, Lurie D, Lauer C, Vetter BH.

Gynecol Obstet Invest. 1993;36(3):136-40.

PMID:
8244184
10.

Serial examination of 20,248 newborn fetuses and infants: correlations between drug exposure and major malformations.

Queisser-Luft A, Eggers I, Stolz G, Kieninger-Baum D, Schlaefer K.

Am J Med Genet. 1996 May 3;63(1):268-76.

PMID:
8723120
11.

Pregnancy outcomes after first-trimester vaginitis drug therapy.

Rosa FW, Baum C, Shaw M.

Obstet Gynecol. 1987 May;69(5):751-5.

PMID:
3574801
12.

The triple risk hypotheses in sudden infant death syndrome.

Guntheroth WG, Spiers PS.

Pediatrics. 2002 Nov;110(5):e64. Review.

PMID:
12415070
13.

Hormone load tests in the first half of pregnancy--a diagnostic and therapeutic approach.

Gerhard I, Runnebaum B.

Biol Res Pregnancy Perinatol. 1984;5(4):157-73.

PMID:
6084523
14.

Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant.

Thaithumyanon P, Limpongsanurak S, Praisuwanna P, Punnahitanon S.

J Med Assoc Thai. 2005 Nov;88(11):1506-13.

PMID:
16471094
15.

Oral contraceptive use after conception in relation to the risk of congenital urinary tract anomalies.

Li DK, Daling JR, Mueller BA, Hickok DE, Fantel AG, Weiss NS.

Teratology. 1995 Jan;51(1):30-6.

PMID:
7597655
16.

17-Hydroxyprogesterone level as a marker for corpus luteum function in aborters versus nonaborters.

Check JH, Vaze MM, Epstein R, Wu CH, Quattrocchi J, Vetter B.

Int J Fertil. 1990 Mar-Apr;35(2):112-5.

PMID:
1970979
17.

Congenital malformations in pregnancies complicated by NIDDM.

Towner D, Kjos SL, Leung B, Montoro MM, Xiang A, Mestman JH, Buchanan TA.

Diabetes Care. 1995 Nov;18(11):1446-51.

PMID:
8722068
18.

Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations.

Källén BA, Otterblad Olausson P.

Birth Defects Res A Clin Mol Teratol. 2007 Apr;79(4):301-8.

PMID:
17216624
19.

Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy.

Wyatt JW, Frias JL, Hoyme HE, Jovanovic L, Kaaja R, Brown F, Garg S, Lee-Parritz A, Seely EW, Kerr L, Mattoo V, Tan M; IONS study group..

Diabet Med. 2005 Jun;22(6):803-7.

PMID:
15910635
20.

Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.

Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME.

Birth Defects Res A Clin Mol Teratol. 2005 Nov;73(11):888-96.

PMID:
16163683

Supplemental Content

Support Center